PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03317158
• News release

 
Abstracts/Posters/Presentations:

• NM Hahn, MA O’Donnell, JA Efstathiou, M Zahurak, G Rosner, J Smith, MR Kates, TJ Bivalacqua, PT Tran, DY Song, AS Baras, A Matoso, W Choi, KN Smith, DM Pardoll, L Marchionni, B McGuire, B Johnson, T O’Neal, DJ McConkey, TL Rose, M Bjurlin, EA Lim, CG Drake, CB Anderson, DL Lamm, DM Geynisman, MA Hallman, EM Horwitz, E Al-Saleem, DYT Chen, A Kutikov, G Guo, TA Masterson, N Adra, HZ Kaimakliotis. Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Trial). Presented at the Society of Urologic Oncology 2020 Annual Meeting. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.